Home - Medical Policies - Alabama
Policies & Guidelines
- Autism Spectrum Mandate
- Behavioral Health
- Blue Advantage Policies
- Chronic Condition Management
- Genetic Testing Management
- Hemophilia Drug Management
- Medical Policies
- PET, MRI, MRA, CT, CTA/CCTA
- Provider-Administered Drug Policies (Excluding Oncology)
- Provider-Administered Oncology Drug Policies
- Radiation Therapy Management (RTM)
- Self-Administered Drug Policies
- Transgender Services
Genetic Testing Management Policies
Current Genetic Testing Policies
Effective March 1, 2020, Blue Cross and Blue Shield of Alabama partners with AIM Specialty Health®, an independent company, to administer genetic testing solutions for our customers.
Third Party Disclaimer
You are about to leave Blue Cross and Blue Shield of Alabama’s website and enter a website operated by AIM Specialty Health®. AIM is our business associate and is an independent company that provides diagnostic testing, information and services. AIM has agreed to follow Blue Cross' privacy and security policies regarding the confidentiality and protection of your personal health information.
To continue to the AIM Specialty Health website, click "Accept" below.
Draft Genetic Testing Policies
Genetic Testing
The following policies supersede the AIM Guidelines for:
Node: bclrgrpappp1002.corp.bcbsal.org:8080